Cannabis Cessation, Inflammatory Markers and Schizophrenia

Roméo, Bruno; Lestra, Valentine; Martelli, Catherine; Benyamina, Aminé; Hamdani, Nora

doi:10.1080/15504263.2021.2013697

Cited by 7 publications

(18 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, schizophrenia was reported to be associated with increased proinflammatory cytokines that may persist despite cannabis use. 27 Stratification of the results according to level of cannabis use did not yield significant results either. This may suggest the difficulty of accurately gauging the true usage patterns, whether due to inaccurate claims by study participants and/or the inability to determine volume and frequency of use via blood testing.…”

Section: Discussionmentioning

confidence: 88%

See 1 more Smart Citation

Inflammation Markers Among Schizophrenia Patients Who Use Cannabis

Fridman,

Bloemhof-Bris,

Weizman

et al. 2023

Clin Neuropharm

View full text Add to dashboard Cite

Objectives The mechanism of inflammation of the immune system, for example, such circulatory markers as the neutrophil-to-lymphocyte ratio (NLR) and mean platelet volume (MPV), has been shown in many studies to be associated with schizophrenia. In addition, it has been shown that the cannabidiol component reduces the activation of the acquired immune system. This study examined the differences in the levels of NLR and MPV among schizophrenia patients with cannabis use versus those without. Methods In 2019 to 2020, a retrospective cross-sectional study was conducted based on digital medical records. Demographic, clinical, and complete blood cell count data were collected from records of rehospitalization of active psychotic schizophrenia inpatients. Data on NLR, MPV values, and demographic and clinical characteristics were compared between the groups and according to the degree of prevalence of cannabis use. Results No differences were found in the NLR and MPV values between the groups. Conclusion The results were contrary to our expectations. These results may be explained by the presentation of a “pseudo-balanced” picture created when multiple processes affect inflammatory indices.

show abstract

Section: Discussionmentioning

confidence: 88%

“…This “lack of finding” may be related to the multidirectional effects mentioned previously. Furthermore, schizophrenia was reported to be associated with increased proinflammatory cytokines that may persist despite cannabis use 27 …”

Section: Discussionmentioning

confidence: 99%

Inflammation Markers Among Schizophrenia Patients Who Use Cannabis

Fridman,

Bloemhof-Bris,

Weizman

et al. 2023

Clin Neuropharm

View full text Add to dashboard Cite

show abstract

“…The impact of cannabis use on inflammatory markers in patients with psychiatric disorders has been evaluated in few studies (24–28) (Miller et al ., 2018; Goetz & Miller, 2019; Gibson et al ., 2020; Corsi-Zuelli et al ., 2021; Romeo et al ., 2022) (25–29). Levels of specific inflammatory markers such as IL-6, IFN-G and CRP were found to be lower among cannabis users as compared to non-users (Miller et al ., 2018; Gibson et al ., 2020).…”

Section: Discussionmentioning

confidence: 99%

“…These results are in line with ours, as we did not find any difference at baseline between THC users and non-users. To our knowledge, our latest work is the first follow-up of selected inflammatory markers after cannabis cessation in patients with schizophrenia (Romeo et al ., 2022). In this first study, we have shown that CRP levels were lower at baseline in the SCZ THC + group, whereas no difference was observed at 4 weeks between the two groups, suggesting a restoration of low-grade inflammation after cannabis cessation.…”

Section: Discussionmentioning

confidence: 99%

“…Few studies have investigated the impact of cannabis consumption on inflammatory markers with psychiatric disorders. Recently, we have found in a small sample, that cannabis cessation increases inflammatory markers such as high sensitivity C-reactive protein (hsCRP) and lymphocyte count, as compared to non-cannabis users, cannabis users with schizophrenia display lower levels of inflammation (Romeo et al ., 2022). These observations were in line with other studies (Miller et al ., 2018; Gibson et al ., 2020) although with discrepancy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Increased markers of inflammation after cannabis cessation and their association with psychotic symptoms

Roméo

Lestra

Martelli

et al. 2023

Acta Neuropsychiatr.

Self Cite

View full text Add to dashboard Cite

Introduction: A dysbalance of the immune system in psychotic disorders has been well investigated. However, despite a higher prevalence of cannabis (THC) consumption in patients with psychosis, few studies have investigated the impact of this use on inflammatory markers. Methods: One hundred and two inpatients were included in this retrospective study. Leukocytic formula, hsCRP, fibrinogen levels and urinary THC were measured, and comparisons were performed at baseline and after 4 weeks of cannabis cessation between cannabis users (THC+) and non-users (THC-). Results: After cannabis cessation, we found a greater increase of leucocyte level (p < 0.01), monocyte level (p = 0.05) and a statistical trend to a highest increase of lymphocyte level (p = 0.06) between baseline and 4 weeks in the THC+ group as compared to the THC- group. At 4 weeks, highest leucocyte (p = 0.03), lymphocyte (p = 0.04) and monocyte (p < 0.01) counts were found in the THC+ group whereas at baseline no difference was found. A positive correlation was found between monocyte count at 4 weeks and baseline PANSS negative subscore (p = 0.045) and between the variation of monocyte count between baseline and 4 weeks and the PANSS total score at 4 weeks (p = 0.05). Conclusion: THC cessation is associated with an increase in inflammatory markers, including white blood cell, lymphocyte, and monocyte levels, which correlates with symptomatology of patients with psychosis.

show abstract

Journal of Dual Diagnosis: Highlights From 2022

Brown

2023

Journal of Dual Diagnosis

View full text Add to dashboard Cite

Cannabis Cessation, Inflammatory Markers and Schizophrenia

Cited by 7 publications

References 56 publications

Inflammation Markers Among Schizophrenia Patients Who Use Cannabis

Inflammation Markers Among Schizophrenia Patients Who Use Cannabis

Increased markers of inflammation after cannabis cessation and their association with psychotic symptoms

Journal of Dual Diagnosis: Highlights From 2022

Contact Info

Product

Resources

About